van der Flier, Wiesje M. http://orcid.org/0000-0001-8766-6224
de Vugt, Marjolein E.
Smets, Ellen M. A. http://orcid.org/0000-0002-8145-8595
Blom, Marco
Teunissen, Charlotte E. http://orcid.org/0000-0002-4061-0837
Funding for this research was provided by:
ZonMw (#73305095007)
Article History
Received: 1 December 2022
Accepted: 21 March 2023
First Online: 18 May 2023
Competing interests
: Research programs of W.M.v.d.F. have been funded by ZonMw, NWO, EU-FP7, EU-JPND, Alzheimer Nederland, Hersenstichting CardioVascular Onderzoek Nederland, Health~Holland, Topsector Life Sciences & Health, Stichting Dioraphte, Gieskes-Strijbis Fonds, Stichting Equilibrio, Edwin Bouw Fonds, Pasman Stichting, Stichting Alzheimer and the Neuropsychiatrie Foundation, Philips, Biogen MA, Novartis NL, Life-MI, AVID, Roche, Eisai, Fujifilm and Combinostics. W.M.v.d.F. holds the Pasman chair. W.M.v.d.F. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). W.M.v.d.F. has performed contract research for Biogen MA and Boehringer Ingelheim. All funding is paid to her institution. W.M.v.d.F. has been an invited speaker at Biogen MA, Danone, Eisai, WebMD Neurology (Medscape), Springer Healthcare, the European Brain Council and Novo Nordisk. W.M.v.d.F. is a consultant to the Oxford Health Policy Forum, Roche and Biogen MA. W.M.v.d.F. participated on the advisory boards of Biogen MA, Roche and Eli Lilly. All funding is paid to her institution. W.M.v.d.F. is member of the steering committee of PAVE and Think Brain Health. W.M.v.d.F. was an associate editor of Alzheimer’s Research and Therapy in 2020–2021. W.M.v.d.F. is an associate editor at Brain. M.E.d.V. reports no disclosures. E.M.A.S. reports no disclosures. M.B. is the scientific director of Alzheimer Nederland. Research of C.E.T. is supported by the European Commission (Marie Curie International Training Network, grant agreement 860197 (MIRIADE), Innovative Medicines Initiatives 3TR (Horizon 2020, grant 831434), EPND (IMI 2 Joint Undertaking (JU), grant 101034344) and JPND (bPRIDE)), the National MS Society (Progressive MS Alliance), the Alzheimer Association, Health Holland, the Dutch Research Council (ZonMw), the Alzheimer Drug Discovery Foundation, the Selfridges Group Foundation and Alzheimer Netherlands. C.E.T. is a recipient of ABOARD, which is a public–private partnership receiving funding from ZonMw (73305095007) and Health~Holland, Topsector Life Sciences & Health (PPP allowance, LSHM20106). C.E.T. has a collaboration contract with ADx NeuroSciences, Quanterix and Eli Lilly and performed contract research or received grants from AC Immune, AXON Neuroscience, BioConnect, Bioorchestra, Brainstorm Therapeutics, Celgene, EIP Pharma, Eisai, Fujirebio, Grifols, Instant NanoBiosensors, Merck, Novo Nordisk, PeopleBio, Roche, Siemens, Toyama and Vivoryon. C.E.T. serves on editorial boards of Medidact Neurologie–Springer, Alzheimer Research and Therapy, Neurology: Neuroimmunology and Neuroinflammation. C.E.T. had speaker contracts for Roche, Grifols and Novo Nordisk. All funding is paid to her institution.
Free to read: This content has been made available to all.